Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERAP2 | Q6P179 | 12/20 | 0.59 |
| ▸ | ERAP1 | Q9NZ08 | 10/20 | 0.59 |
| ▸ | IL1RN | P18510 | 7/20 | 0.59 |
| ▸ | ANPEP | P15144 | 1/20 | 0.57 |
| ▸ | NMBR | P28336 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | ECE1 | P42892 | 1/20 | 0.56 |
| ▸ | LNPEP | Q9UIQ6 | 4/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8097660 | 0.94 | ERAP1 (0.64) | ERAP2ERAP1IL1RNNMBRLNPEP | |
| SCHEMBL15526241 | 0.94 | ERAP1 (0.64) | ERAP2ERAP1IL1RNNMBRLNPEP | |
| SCHEMBL17547907 | 0.91 | ERAP1 (0.59) | ERAP2ERAP1IL1RNANPEPNMBR | |
| SCHEMBL644843 | 0.91 | MEN1 (0.62) | ERAP2ERAP1IL1RNANPEPMEN1 | |
| SCHEMBL27785992 | 0.87 | ERAP2 (0.59) | ERAP2ERAP1IL1RNNMBRECE1 | |
| SCHEMBL27785996 | 0.87 | ERAP2 (0.59) | ERAP2ERAP1IL1RNNMBRECE1 | |
| SCHEMBL27855349 | 0.87 | ECE1 (0.55) | ERAP2ERAP1IL1RNNMBRMEN1 | |
| SCHEMBL30800612 | 0.87 | ERAP2 (0.64) | ERAP2ERAP1IL1RNANPEPMEN1 | |
| SCHEMBL17547908 | 0.87 | CTSC (0.58) | ERAP2ERAP1IL1RNANPEPNMBR | |
| SCHEMBL20829978 | 0.86 | OPRK1 (0.62) | ERAP2ERAP1IL1RNANPEPMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2013123574-A1 | ORALLY BIOAVAILABLE DERIVATIVES OF D-GAMMA-GLUTAMYL-D-TRYPTOPHAN | APOTEX TECHNOLOGIES INC. (CA) | 2013-08-29 | — | — | WO | disclosed |
| US-8507449-B2 | Crystalline D-isoglutamyl-D-tryptophan and the mono ammonium salt of D-isoglutamyl-D-tryptophan | APOTEX TECHNOLOGIES INC. (CA) | 2013-08-13 | — | — | US | disclosed |
| US-8476235-B2 | Crystalline D-isoglutamyl-D-tryptophan and the mono ammonium salt of D-isoglutamyl-D-tryptophan | APOTEX TECHNOLOGIES INC. (CA) | 2013-07-02 | — | — | US | disclosed |
| US-20130060048-A1 | CRYSTALLINE D-ISOGLUTAMYL-D-TRYPTOPHAN AND THE MONO AMMONIUM SLAT OF D-ISOGLUTAMYL-D-TRYPTOPHAN | APOTEX TECHNOLOGIES INC. (CA) | 2013-03-07 | — | — | US | disclosed |
| US-20130059791-A1 | CRYSTALLINE D-ISOGLUTAMYL-D-TRYPTOPHAN AND THE MONO AMMONIUM SLAT OF D-ISOGLUTAMYL-D-TRYPTOPHAN | APOTEX TECHNOLOGIES INC. (CA) | 2013-03-07 | — | — | US | disclosed |
| US-20120157387-A1 | ORALLY BIOAVAILABLE D-GAMMA-GLUTAMYL-D-TRYPTOPHAN | APOTEX TECHNOLOGIES INC. (CA) | 2012-06-21 | — | — | US | disclosed |
| US-8119606-B2 | Crystalline D-isoglutamyl-D-tryptophan and the mono ammonium salt of D-isoglutamyl-D-tryptophan | Apotex Technologies (CA) | 2012-02-21 | — | — | US | disclosed |
| US-20100016243-A1 | CRYSTALLINE D-ISOGLUTAMYL-D-TRYPTOPHAN AND THE MONO AMMONIUM SALT OF D-ISOGLUTAMYL-D-TRYPTOPHAN | APOTEX TECHNOLOGIES INC. (CA) | 2010-01-21 | — | — | US | disclosed |
| EP-2121728-A1 | CRYSTALLINE D-ISOGLUTAMYL-D-TRYPTOPHAN AND THE MONO AMMONIUM SALT OF D-ISOGLUTAMYL- D-TRYPTOPHAN | Apotex Technologies Inc. (CA) | 2009-11-25 | — | — | EP | disclosed |
| WO-2008064465-A1 | CRYSTALLINE D-ISOGLUTAMYL-D-TRYPTOPHAN AND THE MONO AMMONIUM SALT OF D-ISOGLUTAMYL- D-TRYPTOPHAN | APOTEX TECHNOLOGIES INC. (CA) | 2008-06-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130060048-A1 | CRYSTALLINE D-ISOGLUTAMYL-D-TRYPTOPHAN AND THE MONO AMMONIUM SLAT OF D-ISOGLUTAMYL-D-TRYPTOPHAN | AADAT, DLST, HTT | ERAP2 2902/4885ERAP1 2854/4885IL1RN 3008/4885 |
| US-20100016243-A1 | CRYSTALLINE D-ISOGLUTAMYL-D-TRYPTOPHAN AND THE MONO AMMONIUM SALT OF D-ISOGLUTAMYL-D-TRYPTOPHAN | DDC, AADAT, GLUL | ERAP2 2964/4885ERAP1 2880/4885IL1RN 3498/4885 |
| US-20120157387-A1 | ORALLY BIOAVAILABLE D-GAMMA-GLUTAMYL-D-TRYPTOPHAN | TPH1, TPH2, GLUL | ERAP2 1204/4885ERAP1 1231/4885IL1RN 3653/4885 |
| US-20130059791-A1 | CRYSTALLINE D-ISOGLUTAMYL-D-TRYPTOPHAN AND THE MONO AMMONIUM SLAT OF D-ISOGLUTAMYL-D-TRYPTOPHAN | AADAT, DLST, HTT | ERAP2 2902/4885ERAP1 2854/4885IL1RN 3008/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.